1-苄基-2-哌啶酮 | 4783-65-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苄基-2-哌啶酮
• 中文别名: 1-苯甲基-2-哌啶酮
• 英文名称: N-benzyl-2-piperidinone
• 英文别名: 1-benzylpiperidin-2-one
• CAS: 4783-65-7
• 化学式: C₁₂H₁₅NO
• mdl: MFCD00464162
• 分子量: 189.257
• InChiKey: MLEGMEBCXGDFQT-UHFFFAOYSA-N

物化性质

• 熔点：
  116-118 °C
• 沸点：
  147 °C/0.125 mmHg (lit.)
• 密度：
  1.07 g/mL at 25 °C (lit.)
• 闪点：
  >230 °F
• 稳定性/保质期：
  在常温常压下稳定，避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8℃

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product name : 1-Benzyl-2-piperidone

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
According to Regulation (EC) No1272/2008
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
According to European Directive 67/548/EEC as amended.
Irritating to eyes, respiratory system and skin.
Label elements
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Hazard symbol(s)
Xi Irritant
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36 Wear suitable protective clothing.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Formula : C12H15NO
Molecular Weight : 189,25 g/mol
CAS-No. EC-No. Index-No. Classification Concentration
1-Benzyl-2-piperidone
4783-65-7 - - Skin Irrit. 2; Eye Irrit. 2; STOT -
SE 3; H315, H319, H335
Xi, R36/37/38
For the full text of the H-Statements mentioned in this Section, see Section 16.

---

Section 4. FIRST AID MEASURES
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special protective equipment for fire-fighters
Wear self contained breathing apparatus for fire fighting if necessary.

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.
Evacuate personnel to safe areas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Normal measures for preventive fire protection.
Conditions for safe storage
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully
resealed and kept upright to prevent leakage. Store in cool place.

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Personal protective equipment
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with
multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to
engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Hand protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without
touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves
after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the
standard EN 374 derived from it.
Eye protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and
approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin and body protection
impervious clothing, The type of protective equipment must be selected according to the concentration
and amount of the dangerous substance at the specific workplace.
Hygiene measures
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at
the end of workday.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Form liquid
Colour colourless
Safety data
pH no data available
Melting point 147 °C
Boiling point 147 °C at 0,167 hPa - lit.
Flash point 110 °C - closed cup
Ignition temperature no data available
Lower explosion limit no data available
Upper explosion limit no data available
Density 1,07 g/cm3 at 25 °C
Water solubility no data available

---

Section 10. STABILITY AND REACTIVITY
Chemical stability
Stable under recommended storage conditions.
Conditions to avoid
no data available
Materials to avoid
Strong oxidizing agents
Hazardous decomposition products
Hazardous decomposition products formed under fire conditions. - Carbon oxides, nitrogen oxides (NOx)

---

Section 11. TOXICOLOGICAL INFORMATION
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional
waste disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
ADR/RID
Not dangerous goods
IMDG
Not dangerous goods
IATA
Not dangerous goods

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.

---

Section 16. OTHER INFORMATION
Text of H-code(s) and R-phrase(s) mentioned in Section 3
Eye Irrit. Eye irritation
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Skin Irrit. Skin irritation
STOT SE Specific target organ toxicity - single exposure
Xi Irritant
R36/37/38 Irritating to eyes, respiratory system and skin.
Further information
Copyright 2010 Co. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used
only as a guide. The information in this document is based on the present state of our knowledge and is
applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee
of the properties of the product. Co., shall not be held liable for any damage resulting from
handling or from contact with the above product. See reverse side of invoice or packing slip for additional
terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  1-苄基-2-哌啶酮 在 2-氯蒽醌 、 cobalt(II) diacetate tetrahydrate 、 二甲基乙二醛肟 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 36.0h， 以87%的产率得到1-苄基1,2-二氢吡啶-2-酮
  参考文献：
  名称：

  有机光氧化还原/钴双催化实现脂肪族化合物的位点选择性无受体脱氢

  摘要：

  脂肪族催化脱氢 (CDA) 在有机合成中的价值在很大程度上仍未得到充分探索。已知的均相 CDA 系统通常需要使用牺牲氢受体（或氧化剂）、贵金属催化剂和苛刻的反应条件，因此将大多数现有方法限制为非或低官能化烷烃的脱氢。在这里，我们描述了一种可见光驱动的双催化剂系统，该系统由廉价的有机光氧化还原和贱金属催化剂组成，用于室温、无受体 CDA (Al-CDA)。该过程由光激发的 2-氯蒽醌引发，涉及脂肪族的 H 原子转移 (HAT) 形成烷基自由基，然后与钴肟反应生成烯烃和 H 2. 这种操作简单的方法能够将容易获得的化学原料直接脱氢成多种官能化的烯烃。例如，我们首次证明了硫醚和酰胺在无氧化剂条件下分别脱饱和为烯基硫醚和烯酰胺。此外，14 种生物相关分子和药物成分的后期脱氢和合成说明了该系统卓越的位点选择性和官能团耐受性。机理研究揭示了双重 HAT 过程，并提供了对反应性和位点选择性起源的见解。

  DOI：

  10.1021/jacs.1c05479
• 作为产物：
  描述：

  1-苄基1,2-二氢吡啶-2-酮 在 nickel-copper 作用下， 220.0~226.0 ℃ 、2.94 MPa 条件下， 生成 1-苄基-2-哌啶酮
  参考文献：
  名称：

  Raeth, Justus Liebigs Annalen der Chemie, 1931, vol. 489, p. 107,117

  摘要：

  DOI：

文献信息

• Npy antagonists, preparation and uses
  申请人：Botez Iuliana

  公开号：US20090233910A1

  公开（公告）日：2009-09-17

  The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

  本发明涉及新颖化合物，它们的制备和用途，特别是在治疗方面的用途。更具体地说，它涉及至少具有两个芳香环的衍生化合物，它们的制备和用途，特别是在人类或动物健康领域。这些化合物对存在于中枢和外周神经系统中的神经肽Y（NPY）的生物受体具有亲和力。本发明的化合物优选为NPY拮抗剂，更具体地说是NPY Y1亚型的拮抗剂，因此可用于治疗或预防涉及NPY的任何疾病。本发明还涉及含有所述化合物的药物组合物，其制备和用途，以及使用所述化合物的治疗方法。
• SUBSTITUTED SULFONAMIDE COMPOUNDS
  申请人：OBERBOERSCH Stefan

  公开号：US20080153843A1

  公开（公告）日：2008-06-26

  Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.

  磺胺取代物，其制备方法，含有这些化合物的药物组合物，以及磺胺取代物在治疗或抑制疼痛和/或各种疾病或疾病状态中的用途。
• Zur Cyclisierung von α-(2-Mercapto- bzw. -2-Amino-benzoyl)-lactamen; Synthese von Benzothiopyrano [4,3-b]pyrrolinonen sowie von Pyrrolino- bzw. Tetrahydropyridino [3,2-c] chinolinonen1)
  作者：Fritz Eiden、Egmont Baumann

  DOI：10.1002/ardp.19833161102

  日期：——

  Die Mercapto‐ bzw. Methylamino‐benzoyllactame 6a, 6b, 6d, 6e und 6f lassen sich durch Erhitzen in die Benzothiopyrano‐pyrrolinone bzw. Pyrrolino‐chinolinone 8a, 8b, 8d, 8e und 8f überführen, wobei nach Pyridinhydrochlorid‐Zusatz die N‐Methylgruppe des Pyrrolinrings unter Bildung von 8c bzw. 8g abgespalten wird. Aus dem Acylpyridon 6i kann so das Tetrahydropyridino‐chinolinon 18 gewonnen werden.

  巯基-或甲氨基-苯甲酰内酰胺 6a、6b、6d、6e 和 6f 可通过加热转化为苯并噻喃-吡咯啉酮或吡咯啉-喹啉酮 8a、8b、8d、8e 和 8f，其中 N-吡咯的甲基环分开形成8c和8g，分别。四氢吡啶-喹啉酮18可由酰基吡啶酮6i得到。
• [EN] MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS<br/>[FR] MULTIPLES A(NTA)GONISTES DE D2/ANTAGONISTES DE H3 POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS AU SNC
  申请人：AAPA B V

  公开号：WO2015069110A1

  公开（公告）日：2015-05-14

  The present invention relates to compounds compound according to Formula (III); and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have D2receptor antagonist/(partial) agonist effects and H3antagonistic effects, pharmaceutical compositions thereof, and methods of using them for application in the prophylaxis or treatment of CNS disorders.

  本发明涉及按照式（III）的化合物；以及其药学上可接受的盐、水合物和溶剂合物。这些化合物具有D2受体拮抗/(部分)激动剂效应和H3拮抗效应，以及其药物组合物，以及将其用于预防或治疗中枢神经系统疾病的方法。
• 可见光或近可见光引发的选择性脱除苄基、烯丙基和炔丙基类保护基的方法
  申请人：云南大学

  公开号：CN113501779B

  公开（公告）日：2023-06-23

  本发明提供了一种可见光或近可见光引发的选择性脱除苄基、烯丙基和炔丙基类保护基的方法，即含苄基、烯丙基或炔丙基类保护基的底物，在酚催化剂、碱、氢源和光的作用下，通过自由基裂解反应，得到目标选择性脱保护基的产物；本方法操作简单，采用安全清洁的可见光或近可见光为激发条件，试剂便宜易得，反应产率高，反应的化学和区域选择性高，适用于各种底物中苄基、烯丙基和炔丙基类保护基的选择性脱除。